Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | CCR2 | P41597 | 8/20 | 0.39 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17544846 | 0.88 | MMP13 (0.42) | PPARGAGTR1AGTR2 | |
| SCHEMBL17544819 | 0.80 | PDE6D (0.40) | PPARGAGTR1AGTR2 | |
| SCHEMBL17544535 | 0.80 | PDE6D (0.42) | PPARGAGTR1AGTR2 | |
| SCHEMBL17544934 | 0.79 | TP53 (0.41) | — | |
| SCHEMBL17680453 | 0.79 | TP53 (0.39) | — | |
| SCHEMBL17670366 | 0.77 | MMP13 (0.40) | AGTR1AGTR2 | |
| SCHEMBL17680457 | 0.77 | MMP13 (0.40) | AGTR1AGTR2TBXA2R | |
| SCHEMBL17670499 | 0.77 | MMP13 (0.40) | AGTR1AGTR2 | |
| SCHEMBL17670353 | 0.77 | MMP13 (0.40) | AGTR1AGTR2TBXA2R | |
| SCHEMBL17683831 | 0.77 | MMP13 (0.40) | PPARGAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | PHF8, KDM3A, PHF2 | PPARG 2122/4885CCR2 3833/4885PIK3C2B 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.